Streetbeat News

SCLX

Scilex Holding Company

https://www.scilexholding.com

Industry

Drug Manufacturers - General

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Open

0.67

Mkt cap

117M

Volume

5M

High

0.68

P/E Ratio

-0.46

52-wk high

2.63

Low

0.54

Div yield

N/A

52-wk low

0.54

Scilex Holding Co (SCLX) and Ya II PN have mutually agreed to terminate their Amended and Restated Standby Equity Purchase Agreement, initially dated February 8, 2023, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 5:49 pm

Scilex Holding Company (NASDAQ:SCLX) announced its intention to seek FDA approval for a label modification of Gloperba to include dosing flexibility for patients with renal impairment. The proposed adjustments include dose adjustments for patients with mild or moderate renal or hepatic impairment, a starting dose of 0.3 mg/day for those with severe renal impairment, and a total recommended dose of 0.3 mg twice a week for patients undergoing dialysis.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 3:02 pm

Scilex Holding Company has reached a settlement agreement with Takeda Pharmaceuticals to resolve a Paragraph IV patent infringement lawsuit. This lawsuit was related to Scilex's filing of a supplemental New Drug Application (sNDA) with the FDA, aiming to expand the label for Gloperba.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 1:00 pm

Scilex Holding Company (SCLX) has responded to Health Canada's questions regarding the product composition of ELYXYB, an FDA-approved oral solution for acute migraine treatment. ELYXYB is under review by Health Canada for approval, with a decision expected in approximately 12 months. The drug is noted for its fast action and potential for low gastrointestinal side effects compared to other NSAIDs. The Canadian migraine therapeutics market is estimated to reach $400 million by 2025.

Portfolio Pulse from Happy Mohamed

March 18, 2024 | 1:04 pm

Scilex Pharmaceuticals Inc. has entered into a definitive mutual release and settlement agreement with Virpax Pharmaceuticals, Inc. This agreement relates to a previously announced term sheet concerning the release and settlement between the two companies.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 1:04 pm

Scilex Holding Company announced the launch of Gloperba, the first FDA-approved liquid oral colchicine for gout prophylaxis, priced at $595 per 150ml. Set to launch in the first half of 2024, Gloperba targets over 70% of gout patients with comorbid conditions requiring dose adjustments. The U.S. gout treatment market is expected to reach $2.0 billion by 2028. Scilex's direct distribution network and experienced commercial team, which successfully launched ZTlido and Elyxyb, positions it well for Gloperba's distribution.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 2:04 pm

Scilex Holding Company (SCLX) announced that the Creditors' Committee of Sorrento Therapeutics (SRNEQ) has filed a motion with the U.S. Bankruptcy Court to extend the lockup period for the shares distributed as a dividend to Sorrento's stockholders until September 2024. These shares were initially distributed on January 19, 2023, with a lockup period set to expire on March 31, 2024. The decision by the court is pending.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 6:55 am

U.S. stocks traded higher with the Nasdaq Composite gaining over 1%. Energy shares rose by 1.4% as crude oil prices increased by 2.3%. BioVie Inc., Cardiff Oncology, and The RealReal reported significant gains following positive updates. Conversely, Sidus Space, Fisker Inc., and Scilex Holding experienced sharp declines. Fisker's drop was due to preliminary Q4 revenue results below estimates and concerns about its ongoing viability.

Portfolio Pulse from Avi Kapoor

March 01, 2024 | 7:32 pm

Zscaler, Inc. (ZS) shares fell by 10.1% following its Q2 earnings report, despite better-than-expected results. Other stocks showed significant movement, with BioVie Inc. (BIVI) and Adial Pharmaceuticals, Inc. (ADIL) among the top gainers. Losers included GigCapital5, Inc. (GIA) and Fisker Inc. (FSR), with FSR dropping 44.6% due to concerns about its going concern status.

Portfolio Pulse from Avi Kapoor

March 01, 2024 | 6:19 pm

In Friday's intraday session, several healthcare stocks experienced significant movements. Adial Pharmaceuticals, BioVie, Cardiff Oncology, Myomo, Altamira Therapeutics, and MSP Recovery were among the gainers, with increases ranging from 24.11% to 58.8%. Conversely, Scilex Holding, Precision BioSciences, DermTech, Vivani Medical, Gritstone Bio, and Humacyte saw declines between 20.81% and 36.4%. Notably, Cardiff Oncology and DermTech released their Q4 earnings reports yesterday.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 5:35 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.